Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03564782 · ClinicalTrials.gov registry record · Early Phase 1
Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
A Early Phase 1 study, sponsored by Istari Oncology.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03564782: Completed Early Phase 1 study, sponsored by Istari Oncology.
NCT03564782 is a Early Phase 1 study that has completed, run by Istari Oncology. The registered enrollment target is 5 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03564782, a Early Phase 1 study, has completed, sponsored by Istari Oncology.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a pilot study to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with invasive breast cancer.
Primary Outcome
To describe the change in the amount of tumor infiltrating immune cells in tumor tissue pre- and post-injection of PVSRIPO
Interventions
- BIOLOGICAL PVSRIPO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-06-30 |
| Est. Completion | 2022-04-11 |
| Phase | Early Phase 1 |
What the finished NCT03564782 record still lists
NCT03564782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which PVSRIPO is the first listed.
NCT03564782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03564782 about?
NCT03564782 is a clinical study titled "Examining Bioactivity of PVSRIPO in Invasive Breast Cancer". This is a pilot study to examine PVSRIPO bioactivity in tumor tissue after intratumoral administration of PVSRIPO in women with invasive breast cancer.
What is the current status of trial NCT03564782?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2019-06-30. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT03564782?
The interventions under investigation include: PVSRIPO (BIOLOGICAL).
Who is sponsoring clinical trial NCT03564782?
This trial is sponsored by Istari Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03564782's enrollment target sits among peer trials
5 1888th of 2000 higher than 80 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI